Poor long-term recovery after critical COVID-19 during 12 months longitudinal follow-up

Abstract

Objectives

This study aimed to describe the burden of illness and impact on health and working situation among former intensive care patients treated for COVID-19.

Methods

A prospective cohort study was performed at one intensive care unit of a university hospital in Sweden during the first wave of COVID-19 in spring 2020. The burden of illness in health status, cognitive, physical, and psychological outcomes, and working situation were assessed at four and 12 months after discharge from intensive care, using nine validated instruments.

Results

Forty-six participants treated for COVID-19 participated in both follow-ups and were included in this study. General fatigue was reported by 37 of 46 participants (82%) at both follow-ups (p = 1.000). For overall health status 28 (61%) participants at the first follow-up and 26 (57%) (p = 0.414) at the second reported lower values than the general population. Cognitive impairment was seen in 22 (52%) participants at four months and in 13 (31%) at 12 months (p = 0.029). The proportion of participants on sick-leave decreased between the first and second follow-up (24% vs 13%, p = 0.025), but the proportion of participants working full-time was almost the same at both follow-ups (35% vs 37%, p = 0.317).

Conclusions

The burden of illness of patients treated in intensive care due to COVID-19 included cognitive, physical, and psychological impacts. Cognitive functions were improved after 12 months, but no clear improvements could be distinguished in the physical or psychological outcome. Higher burden of illness was associated with inability to return to work.

Implications for clinical practice.

• •When resuming life after intensive care and COVID-19, it is important to seriously consider the remaining symptoms.
• •Recovery measurements should be considered after intensive care and COVID-19 which include health status, cognitive, physical, and psychological outcomes.
• •To increase patients’ possibility to return to previous work and life there is a need to highlight the importance of personalized rehabilitation for former intensive care treated COVID-19 patients.

Background

The severe acute respiratory syndrome corona virus 2 caused the Coronavirus disease (COVID-19) pandemic, with over 422 million people worldwide confirmed as infected by February 2022 (WHO, 2022). The first wave of the COVID-19 pandemic, in the spring of 2020, called for an increased number of intensive care unit (ICU) beds. The rate of admission to intensive care among those infected varied between 1.6% and 6.7% in the Nordic countries (Chew et al., 2021). In Sweden, 3472 COVID-19-infected people were treated in intensive care during the first wave. Most had longer ICU stays, a more extended time on mechanical ventilation often in prone position and therefore received sedation for longer than ICU patients before the pandemic (SIR (The Swedish Intensive Care Registry), 2020).

Before the pandemic, ICU patients followed-up after discharge described both positive emotions (Hashem et al., 2016) and a wide range of mental and physical impacts which affected daily life (Geense et al., 2021, Hashem et al., 2016). Female patients tend to report higher frailty and fatigue scores one year after ICU discharge than male patients (Geense et al., 2021). Long-term symptoms and their effects on health status after COVID-19 are now beginning to be reported (Evans et al., 2021, Huang et al., 2021b, Schandl et al., 2021, Sigfrid et al., 2021, Wallin et al., 2021). However, knowledge about the process of recovery after severe COVID-19 with intensive care and especially about the health consequences of long-term symptoms, is lacking. Therefore, this study aimed to describe the burden of illness and its impact on health and working situation among former ICU patients treated for COVID-19.

Methods

Study design and patients

A prospective, longitudinal cohort study design.

The study was performed at a general ICU at a university hospital in Sweden. The treatment and care of COVID-19 patients during the first wave of the pandemic were based on international and national recommendations and continuously updated guidelines. This ICU had eight beds before the pandemic, but temporary ICU beds were set up to manage the increased number of patients. At the peak of the first wave, 23 ICU beds were in use for COVID-19 patients. The criteria for admittance to ICU during the first wave were based on the concept of potential benefit, in accordance with the usual criteria for intensive care in Sweden and included patients in need of high flow nasal oxygen, non-invasive ventilation or invasive ventilation (Swedish Society of Anaesthesiology and Intensive Care (SFAI), 2015).

Patients were eligible to participate in this follow-up study if they had previously been included in an ongoing research project investigating the acute effects of COVID-19 (ClinicalTrials ID NCT04316884). This study had two follow-ups, the first at 3–6 months and the second at 12 months after discharge from the ICU. On both occasions, patients were contacted by telephone and asked to participate. The participants in this follow-up study were admitted to the ICU during the period 13th March–14th July 2020, i.e. the first wave of COVID-19.

Ethical approval

The study was approved by the Swedish Ethical Review Authority (EPM-2020-02697 with revisions 2020-03629, 2020-05758, and 2021-02205) and was performed in accordance with the Declaration of Helsinki as adopted in 1964, and its subsequent revisions. Participants were included after giving informed consent. The study was registered à priori (ClinicalTrials ID: NCT04474249).

Data collection

Participants were contacted and informed about the study at 3–6 months after the discharge from the ICU by telephone by the first or last author. At 12 months the participants were contacted again by telephone by the first or last author. They were invited to individual face-to-face meetings at the hospital within three weeks of these phone calls. Before these meetings, forms for self-reporting outcome assessments were sent by post to the participants (The Multidimensional Fatigue Inventory (MFI20), Generalised Anxiety Disorder 7 (GAD-7), Patient Health Questionnaire 9 (PHQ-9), who were asked to fill them out and bring them to their meeting. At the face-to-face meetings, participants were clinically assessed and evaluated for cognitive and physical performance using clinician reporting outcome assessments (modified Rankin Scale (mRS), Post-COVID-19 Functional Status Scale (PCFS), Clinical Frailty Scale (CFS), self-reporting outcome assessments (EQ-5D-5L, EQ-VAS), and performance outcome assessment (Montreal Cognitive Assessment (MoCA), 6-minute walk test [6MWT]).

Outcomes

Our main outcomes were burden of illness and working situation at four and 12 months after ICU discharge and secondary outcomes were changes in burden of illness and working situation between four and 12 months after ICU discharge. The following outcome measures were assessed.

Living condition

Return to the previous occupational status and place of residence.

Functional status

The modified Rankin Scale (mRS) is a robust, clinician-reported measure; the structured interview was used to monitor the functional status of each patient (Rankin, 1957). Dichotomized mRS scores of 0–2 were defined as no health consequences, with scores of 3–6 defined as remaining health consequences.

The Post-COVID-19 Functional Status Scale (PCFS) was used to quantify current functional outcomes. This clinician-reported scale was adopted for COVID-19 at the beginning of the first wave of the pandemic (Klok et al., 2020). The PCFS is a simple tool to monitor the course of symptoms and their impact on the functional status of patients treated for COVID-19. The scale focuses on relevant aspects of health consequences and everyday life after a COVID-19 infection. The scale has five steps, from 0 (“no limitations in everyday life”) to 4 (“extensive limitations in everyday life”). Dichotomized PCFS scores of 0–2 were defined as no health consequences limiting everyday life, with scores of 3–4 defined as remaining health consequences limiting everyday life.

Frailty

To measure frailty, the Clinical Frailty Scale (CFS) was used (Muscedere et al., 2017). The CFS was used as a clinician-reported tool, comprising nine classes from very fit to terminally ill. A simple visual description was used for categorization. When dichotomized, a CFS score of 5 and above was used as a frailty cut-off.

Health status

The EQ-5D-5L questionnaire was used to measure health status (Rabin and De Charro, 2001). It includes two descriptive sections. The first is a five-question component that explores five dimensions: Mobility, Self-care, Usual activities, Pain/discomfort, and Anxiety/depression. Each dimension is rated on a scale from 1 to 5: no problems, slight problems, moderate problems, severe problems, and extreme problems. A score of ≥ 2 indicates problems, with higher scores indicating greater severity.

The second section is a visual analogue scale (EQ-VAS) and is a measure of self-rated overall health status, ranging from “The best health you can imagine” (100) to “The worst health you can imagine” (0). A mean score of 79.5 in the Swedish population in EQ-VAS was used as cut-off score to define good self-related overall health status (Burström et al., 2020).

Cognitive function

To examine global cognitive function, the Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) was used. It encompasses visuospatial ability, executive function, attention/working memory, episodic memory, and language. The score range is 0–30. A low score indicates worse cognitive performance and a cut-off of 26 was used to define cognitive dysfunction.

Fatigue

The Multidimensional Fatigue Inventory (MFI20) was used to assess fatigue (Smets et al., 1995). This is a 20-item self-report questionnaire covering fatigue and its intensity and nature. It encompasses five different dimensions of fatigue: General fatigue, Physical fatigue, Mental fatigue, Reduced motivation, and Reduced activity. Each subscale contains two positively formulated items (e.g., “I feel very active”) and two negatively formulated items (e.g., “I get tired easily”). Items are rated on a 5-point Likert scale (range 1 “Yes, that is true” to 5 “No, that is not true”) which are summed up to a simple total score for each subscale with a minimum value of 4 (absence of fatigue) and a maximum value of 20. Higher scores indicate higher levels of fatigue. The dimension General fatigue can be used to identify fatigue more generally. Dichotomized MFI20 scores of 4–8 (absence or mild) were defined as no fatigue, with scores of 9–20 (moderate, severe, and very severe) defined as fatigue symptoms.

Anxiety and depression

The self-assessment form Generalised Anxiety Disorder 7-item scale (GAD-7) (Spitzer et al., 2006) was assessed to measure anxiety. The GAD-7 includes seven items rated on a 4-point Likert scale ranging from 0 (“not at all”) to 3 (“nearly every day”). A total score of 0–21 is calculated by summing up all the items. The total score is categorized into minimal (0–4), mild (5–9), moderate (10–14), or severe (15–21) anxiety symptoms. In this study, the GAD-7 score was dichotomized (≥10) as occurrence of generalized anxiety.

The Patient Health Questionnaire 9 (PHQ-9) (Kroenke et al., 2001) was used to measure depression. The PHQ-9 is a self-report scale and includes nine items on a 4-point Likert scale ranging from 0 (“not at all”) to 3 (“nearly every day”). A total score of 0–27 is obtained by summing up all items. The depression symptom severity is categorized into minimal (0–4), mild (5–9), moderate (10–14), moderately severe (15–19), or severe (20–27). In this study, the PHQ-9 score was dichotomized (≥10) as occurrence of depression.

Physical capacity

Physical capacity was assessed using the 6-minute walk test (6MWT) (Crapo et al., 2002). It measures the distance that a person can walk in 6 min on a hard flat surface. A predicted value was calculated for each participant based on age, gender, weight, and height. A lower limit of normal was used as the cut-off point when 6MWT results were dichotomized (Jay and Enright, 2000).

For all instruments except for PCFS, Swedish validated versions were used. PCFS was constructed for COVID-19 patients during the first wave of COVID-19 and was not validated in Swedish when conducting this study.

Statistical analysis

Descriptive statistics and results are presented as frequencies (n), percentages (%), and medians with interquartile ranges (IQRs). The Wilcoxon signed-rank test was used to describe differences over time and the Mann-Whitney U test to analyze differences between groups. Statistical significance was defined as a p-value < 0.05 (two-sided). Statistical analyses were performed using SPSS version 27 (SPSS Inc. Chicago, Illinois, USA). The MFI20, had two missing responses in the domain general fatigue and one missing response in the other domains. The PHQ-9, had six questionnaires with missing responses and the GAD-7 had one questionnaire with a missing response, and questionnaires with missing response were not included in the results.

Results

During the first wave of COVID-19, 123 patients were included. Out of them, three were not diagnosed with COVID-19 and thus excluded. At the time of the first follow-up, 32 had died, 23 declined to participate or were lost to follow-up and one did not return the questionnaire. This resulted in 64 participants in the first follow-up. Eighteen patients were lost to follow-up or declined to participate in the second follow-up (Fig. 1 ). The patients lost to follow-up had less hypertension and more malignancy than those who participated in both follow-ups (Table 1 ). The median time to the first follow-up after discharge from ICU was four months, and 12 months to the second follow-up (Table 2 ). Importantly, no differences were seen in outcomes at four months between those who participated in or were lost to follow-up at 12 months. Those who participated in both follow-ups (n = 46) were included in the final analysis (Fig. 1).

Fig. 1.

Flowchart of COVID-19 patients treated in ICU during the first wave of the pandemic and was included in the follow-up study. ICU: intensive care unit.

Table 1.

Patient’s demographics and clinical characteristics on follow-up at two occasions and patients lost in follow-up.

	n = 46 (follow-up at two occasions)	n = 18 (lost in follow-up)	p-value
Demographics
Age	59 (53–69)	55 (39–73)	0.285
Sex (female)	12 (26%)	5 (28%)	0.891
BMI at admission (n = 44)	29 (27–33)	29 (27–33)	0.629
Comorbidities at admission
Lung disease	13 (28%)	4 (22%)	0.626
Hypertension	26 (56%)	4 (22%)	0.014
Heart failure	0	0	1.000
Ischemic heart disease	3 (6%)	0	0.271
Vascular disease	5 (11%)	1 (6%)	0.515
Malignancy	0	3 (17%)	0.005
Diabetes mellitus	9 (20%)	3 (17%)	0.791
Neurological disease	2 (4%)	0	0.373
Psychiatric disease	3 (6%)	0	0.271
ICU characteristics
SAPS3	52 (46–55)	50 (39–59)	0.515
Length of ICU stay (days)	10 (6–17)	8 (5–12)	0.320
Invasive ventilation therapy (Days with invasive ventilation therapy)	25 (54%) (9 (4–16))	11 (61%) (2 (0–8))	0.627 0.969
Mild ARDS	1 (2%)	2 (11%)	1.000
Moderate ARDS	20 (43%)	7 (39%)	1.000
Severe ARDS	18 (39%)	6 (33%)	1.000
Vasopressor	24 (52%)	9 (50%)	0.877
Renal replacement therapy	6 (13%)	2 (11%)	0.835
Delirium	6 (13%)	1 (6%)	0.392
Critical illness weakness	5 (11%)	2 (11%)	0.978
Length of hospital stay (days)	22 (13–38)	23 (12–32)	0.523
Tertiary education (≥12 years schooling)	26 (56%)	10 (56%)	0.945
Marital status
Living together	36 (78%)	14 (78%)	0.845
Living alone	9 (20%)	4 (22%)
Missing data	1 (2%)

Categorical data presented as number of total, n (percentage) and compared using Wilcoxon signed-rank test. Continuous data presented as median with interquartile range (IQR) and compared with Mann-Whitney U test.

ARDS: Acute respiratory distress syndrome, ICU: intensive care unit, IQR: interquartile range, SAPS3: Simplified acute physiology score-3.

Table 2.

Baseline and outcome data at follow-up in patients who participated in both follow-ups (n = 46).

	Before COVID-19 (n = 46)	4 months (n = 46)	12 months (n = 46)	p value (4 vs 12 months)
Time to follow-up (months)		4 (3.8–4.3)	12 (11.6–12.3)
BMI	29 (27–33)	30 (26–33)	32 (27–35)	<0.001
Place of residence:
Home	46 (100%)	44 (96%)	46 (100%)	0.157
Convalescent/rehabilitation home		2 (4%)
Occupational status:
Working full-time	29 (63%)	16 (35%)	17 (37%)	0.317
Working part-time	3 (6%)	4 (9%)	5 (11%)	0.317
Unemployed	0	1 (2%)	3 (6%)	0.157
Retired	11 (24%)	14 (30%)	15 (33%)	0.317
On sick leave	3 (6%)	11 (24%)	6 (13%)	0.025
Outcome				p value
modified Rankin Scale (mRS) (n = 46)		1 (1–2)	1 (1–2)	1.000
Post-COVID-19 Functional Status Scale (PCFS) (n = 46)		1 (1–2)	1 (1–3)	0.323
Clinical Frailty Scale (CFS) (n = 46)		2 (2–3)	3 (2–4)	0.002
EQ-5D-5L (n = 46)
Mobility		1.5 (1–2)	1 (1–2)	0.819
Self-Care		1 (1–1)	1 (1–1)	0.414
Usual Activity		2 (1–3)	2 (1–3)	0.201
Pain/discomfort		2 (1–3)	2 (1–3)	0.860
Anxiety/Depression		1.5 (1–2)	2 (1–2)	1.000
EQ-VAS		70 (59–85)	75 (50–85)	0.893
Montreal Cognitive Assessment (MoCa) (n = 42)		26 (24–28)	27 (26–29)	0.039
Multidimensional Fatigue Inventory (MFI 20)
General fatigue (n = 44)		14 (10–18)	14.5 (10–17)	0.796
Physical fatigue (n = 45)		14 (8–18)	14 (9–16)	0.539
Mental fatigue (n = 45)		10 (6–14)	9 (6–13)	0.084
Reduced motivation (n = 45)		9 (6–11)	8 (6–12)	0.974
Reduced activity (n = 45)		12 (8–17)	10 (8–15)	0.170
Generalised Anxiety Disorder 7-item scale (GAD-7) (n = 45)		2 (0–7)	2 (0–6)	0.112
Patient Depression Questionnaire 9 (PHQ-9) (n = 40)		4 (1–11)	3 (1–11)	0.211
6-minute walk test (6MWT) (n = 45)		522 (396–597)	525 (415–594)	0.802

Data are presented as number (percentage) or median with interquartile range (IQR).

Categorical data presented as number of total, n (percentage) and compared using Wilcoxon signed-rank test. Continuous data presented as median with interquartile range (IQR) and compared with Mann-Whitney U test.

Demographic and clinical characteristics for the included participants are shown in Table 1. The median age was 59 years and the majority of the participants were men (n = 34, 74%). Twenty-five (54%) had received invasive ventilation and the median length of ICU stay was 10 days (IQR 6–17) (Table 1). Before getting COVID-19, 29 (63%) participants worked full-time and 3 (6%) part-time (Table 2).

The results showed no improvements between the first and second follow-up, except for cognitive function, measured with MoCA, which improved from 26 (24–28) to 27 (26–29), p = 0.039. Impairment increased in frailty from 2 (2–3) to 3 (2–4), p = 0.002 (Table 2). The most common symptom was fatigue, which occurred in 51% (n = 23) to 84% (n = 38) (Fig. 2 ).

Fig. 2.

Dichotomized results of occurrence of burden of illness in health status, cognitive, physical and psychological outcomes at four months and 12 months after discharge from ICU. Presented as precent of number of patients with occurrence of burden of illness. No differences were seen between 4 and 12 months, except for MoCA (p = 0.029). 6MWT: 6-minute walk test, CFS: Clinical Frailty Scale, GAD-7: Generalised Anxiety Disorder 7-item scale, ICU: intensive care unit, MoCA: Montreal Cognitive Assessment, MFI 20: Multidimensional Fatigue Inventory, mRS: modified Rankin Scale, PCFS: Post-COVID-19 Functional Status Scale, PHQ-9: Patient Depression Questionnaire 9. Categorical data presented percentage and compared using Wilcoxon signed-rank test.

No differences were seen between male and female in any of the outcome measures (Supplement Table 1). At the first follow-up, those treated with invasive ventilation scored higher on functional status than those treated non-invasive ventilation, on both the mRS (median 2 (1–2.5) vs 1 (0.5–2), p = 0.011) and the PCFS (median 2 (1–3) vs 1 (0.5–1), p = 0.025). At the second follow-up, the participants who had been treated with invasive ventilation showed reduced activity on the MFI20 (median 14 (9–16) vs 9 (6–14), p = 0.031). For the other outcome measures, no differences were seen (Supplement Table 2).

The proportion of participants on sick leave decreased between the first and second follow-up (24% vs 13%, p = 0.025), but the proportion of participants working full-time was almost the same at both follow-ups (35% vs 37%, p = 0.317) (Table 2). Among the participants who worked before getting COVID-19 and not returned to work at the first follow-up, had longer stays in ICU (p = 0.005) and several of them had been on invasive ventilation (p < 0.001). At the second follow-up, these differences were not seen, but those who had not returned to work were more affected in health status, cognitive function, fatigue, anxiety and depression (Table 3 ).

Table 3.

Outcome related to working situation among patients who worked before COVID-19.

	Working before COVID-19, n = 32			Working before COVID-19, n = 32
	3–6 month	3–6 month		12 month	12 month
	Returned to work, n = 20	Not returned to work, n = 12	p-value	Returned to work, n = 22	Not returned to work, n = 10	p-value
Age	56 (53–61)	58 (50–67)	0.640	56 (52–61)	59 (53–65)	0.370
Sex (female)	5 (25)	1 (8)	0.250	5 (23)	1 (10)	0.400
SAPS3	50 (46–53)	53 (46–57)	0.159	51 (46–56)	51 (46–53)	0.759
Invasiv ventilation therapy (Days with invasive ventilation therapy)	5 (25) 0 (0–1.5)	11 (92) 10.5 (6–22)	0.000 0.000	10 (46) 0 (0–8.5)	6 (60) 7 (0–28)	0.453 0.215
Days in ICU	7 (4–12)	21 (9–37)	0.005	8 (6–14)	15 (3–40)	0.541
Education (≥12 years)	12 (60)	5 (42)	0.322	12 (55)	5 (50)	0.814
Outcome
EQ-5D-5L
Mobility	1 (1–2)	2 (1–2)	0.209	1 (1–1)	2 (2–3)	0.001
Self-Care	1 (1–1)	1 (1–2)	0.477	1 (1–1)	1 (1–2)	0.182
Usual Activity	1 (1–2)	3 (2–5)	0.003	1 (1–2)	3 (2–5)	0.004
Pain/discomfort	2 (1–3)	3 (2–3)	0.307	2 (1–3)	3 (2–3)	0.659
Anxiety/Depression	1 (1–2)	1 (1–3)	0.058	1 (1–2)	2 (2–3)	0.136
EQ-VAS	75 (66–90)	68 (51–80)	0.170	80 (69–93)	53 (48–76)	0.003
MoCA	28 (26–29)	25 (22–28)	0.019	29 (27–29)	28 (26–28)	0.046
MFI General fatigue	10 (6–12)	17 (8–19)	0.104	12 (8–15)	16 (15–18)	0.014
MFI Physical fatigue	12 (8–17)	15 (10–18)	0.407	11 (8–15)	16 (11–19)	0.013
MFI Mental fatigue	12 (6–15)	17 (8–20)	0.082	8 (6–10)	11 (6–18)	0.121
MFI reduced motivation	10 (6–12)	12 (8–16)	0.279	8 (6–11)	8 (6–11)	1.000
MFI reduced activity	8 (6–11)	9 (4–11)	0.967	9 (6–14)	14 (10–17)	0.022
PHQ9	3 (1–8)	7 (1–11)	0.338	2 (0–5)	9 (4–15)	0.012
GAD7	3 (0–4)	4 (0–7)	0.270	1 (0–2)	5 (3–10)	0.002
6MWT	560 (522–629)	410 (363–539)	0.004	558 (505–613)	461 (390–578)	0.132

Categorical data presented as number of total, n (percentage) and compared using Wilcoxon signed-rank test. Continuous data presented as median with interquartile range (IQR) and compared with Mann-Whitney U test. 6MWT: 6-minute walk test, CFS: Clinical Frailty Scale, GAD-7: Generalised Anxiety Disorder 7-item scale, ICU: intensive care unit, MoCA: Montreal Cognitive Assessment, MFI 20: Multidimensional Fatigue Inventory, mRS: modified Rankin Scale, PCFS: Post-COVID-19 Functional Status Scale, PHQ-9: Patient Depression Questionnaire.

Discussion

The main finding of the present study is that the majority of patients reported persistent long-term symptoms that did not improve substantially between 3–6 months and one year after discharge from ICU. In addition, although 87% of patients returned to work during the first year after intensive care for COVID-19, only 35–37% returned to full-time work. The participants were affected in most of the outcome measures, with fatigue being the most common symptom. Improvements over time were only seen in cognitive outcome.

Return to work is a key factor for individuals to return to daily life (Kamdar et al., 2020). In the present study, the number of participants on sick-leave decreased between the first and second follow-up, indicating the ability to return to daily life. Notably, the number of participants back to working full-time was almost the same at both follow-ups. Many participants reported remaining symptoms and a burden of illness in health status, physical, and psychological outcomes at both follow-ups. This may be why the number of participants back in full-time work at 12 months was not larger. Symptoms and burden of illness affect both the well-being of the individual and the general economy and need to be investigated further.

Fatigue after critical illness is shown to have an impact on recovery and the quality of life and may lead to difficulties in daily life as well as economic consequences for the individual (Bench et al., 2021). In our study fatigue was the most common remaining symptom and occurred in all dimensions of fatigue, measured using the MFI20. Furthermore, fatigue seemed to be more common after severe COVID-19 and intensive care than in other ICU patients (Bench et al., 2021). However, how fatigue affects the participants overall health status have not been tested in our study.

The distance of walking among participants during the 6MWT was longer than shown in previous studies in critically ill patients (Parry et al., 2021), but similar to studies of severe COVID-19 sufferers (Huang et al., 2021b, Schandl et al., 2021). This is an interesting finding which needs to be studied further, since the fatigue described by the participants does not correlate well with their actual physical capacity measured with the 6MWT.

The level of frailty measured with the CFS was low. Only a few participants were above the cut-off point for frailty at the first follow-up and none at the second. However, the prevalence of frailty increased over time. Frailty often occurs following critical illness, and also among patients with no frailty before a critical illness, persistent illness may lead to increased frailty over time (Brummel et al., 2020). In this study, frailty was not measured before ICU admission and we can only assume that the majority of participants had no frailty before their COVID-19 infection.

Cognitive impairment occurs in patients treated in intensive care for critical illness, regardless of age or diagnosis (Pandharipande et al., 2013, Rousseau et al., 2021), but we found cognitive improvements over time.

Health status measured using the EQ-VAS revealed lower values than the general population (Burström et al., 2020), but similar values as a population given care for critical illness (Gerth et al., 2019).

One third of patients report presence of anxiety and depression after critical illness and intensive care, which is persistent at a 12-month follow-up (Nikayin et al., 2016, Rabiee et al., 2016). We found similar results, with anxiety reported marginally less often than depression, and a tendency for both anxiety and depression to have decreased at 12 months.

As far as we know, no studies have compared outcome over time for patients treated in intensive care for COVID-19. However, our findings are similar to those of other studies reporting outcomes among patients treated for COVID-19, showing patients to have a burden of illness in several areas (Heesakkers et al., 2022, Huang et al., 2021a, Huang et al., 2021b, Schandl et al., 2021, Seeßle et al., 2021, Zhang et al., 2021, Zhao et al., 2021). The variation in and occurrence of deficits may depend on when follow-up is performed and what instrument is used. We used MoCA, which has been recommended as a core outcome measurement for assessing cognitive function (Needham et al 2017). To assess symptoms and functional status in former ICU patients in a simple way we used the mRS scale (Rankin, 1957). We also used GAD-7 and PHQ-9 to measure anxiety and depression to get a psychiatric perspective. However, mRS, GAD-7 and PHQ-9 have not been widely used in the COVID-19 ICU population, and further investigations would may be useful to fully interpret the results. The overall analysis strategy in this study was not to validate mRS, GAD-7 or PHQ-9 in patients treated for COVID-19, but to be descriptive and generating hypothesis for future studies. There is no consensus on most suitable test for fatigue or at what timepoint the tests should be performed after critical illness and intensive care. These are factors to take into account when interpreting results from different studies. However, by using MFI-20 we gained an increased knowledge of what dimension the patients were most affected in. This study was performed among patients from the first wave of COVID-19, if our results also apply to patients from later waves of COVID-19 needs to be further investigated. However, patients surviving other critical illnesses, show similar burdens of illness after intensive care (Bench et al., 2021, Brummel et al., 2020, Elliott et al., 2014, Geense et al., 2021, Gerth et al., 2019, Hashem et al., 2016, Nikayin et al., 2016, Pandharipande et al., 2013, Parry et al., 2021, Rabiee et al., 2016, Yao et al., 2021) which may indicate that COVID-19 patients do not differ from other ICU-treated patients in that regard. This highlights the importance of personalized rehabilitation and follow-up, to increase the possibility to return to previous work and life, calling for more intervention studies among ICU patients.

Strength and limitations

This study’s strengths included former ICU patients being prospectively followed up over time on two occasions, to examine the development of their burden of illness on health status and cognitive, physical, and psychological outcomes. To reduce the risk of information bias, the study was strengthened through the use of well-validated outcome questionnaires and tests.

We also acknowledge some limitations. The study was performed among patients from the first wave of COVID-19 at a single hospital and thus reflected only the perceptions of patients treated there at that time. However, our COVID-19 population showed similar demographic characteristics as the entire Swedish ICU-treated COVID-19 population during the first wave of COVID-19 (SIR (The Swedish Intensive Care Registry), 2022, Zettersten et al., 2021), suggesting that our cohort was representative for the whole population. A further weakness is that patients were lost between the first and second follow-up, but in this setting a response rate of 67% is relatively high for a population of ICU survivors. Importantly, only minor differences in comorbidities and outcomes at the first follow-up between those who participated in or were lost to the second follow-up indicate that loss to follow-up is not likely to bias the results. In this relatively small population where a wide array of instruments have been used both type 1 and type 2 errors may be expected for any single instrument. However, the picture of limited recovery between four months and 12 months after treatment in ICU is consistent across the board suggesting some measure of reliability of the results.

Conclusions

Former ICU patients had a burden of illness on health status and cognitive, physical, and psychological outcomes at both 3–6 and 12 months after being treated in ICU for severe COVID-19. Most patients were able to return to work within one year of ICU discharge, but only a minority returned to full-time work. No clear improvement in symptoms could be distinguished between four months and one year after ICU discharge, with the exception of a slight improvement in cognitive function. A higher burden of illness was more common in participants who had not returned to work after 12 months.

Data availability

Data is available from the corresponding author on reasonable request pending appropriate permissions and data access agreements (https://doi.org/10.17044/scilifelab.14229410).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

The following are the Supplementary data to this article: